Ideal Features of Topical Antibiotic Therapy for the Treatment of Impetigo: An Italian Expert Consensus Report

Overview

Journal Curr Ther Res Clin Exp

Specialty Pharmacology

Date 2023 Jan 30

PMID 36712177

Authors

Iria Neri

Michele Miraglia Del Giudice

Andrea Novelli

Giuseppe Ruggiero

Giovanni Pappagallo

Luisa Galli

Affiliations

Soon will be listed here.

Abstract

Background: A group of Italian experts in impetigo medical care sought to define 10 statements to describe the ideal characteristics of the best local antibiotic treatments, and to provide relevant information re- garding their appropriate use and prescription that should be considered in clinical practice for impetigo management.

Objective: A group of Italian experts in impetigo medical care sought to define 10 statements to describe the ideal characteristics of the best local antibiotic treatments, and to provide relevant information regarding their appropriate use and prescription that should be considered in clinical practice for impetigo management.

Methods: A consensus on ideal features of antibiotic therapy for the treatment of impetigo was appraised by an online Delphi-based method, based on a panel of 61 infectious disease specialists, pediatricians, and dermatologists coordinated by a scientific committee of 5 experts specializing in impetigo management.

Results: Full or very high consensus was reached on the 10 statements identified to describe the characteristics of the best hypothetic antibiotic therapy for impetigo together with indications for appropriate antibiotics use.

Conclusions: Several criteria have to be considered when selecting topical antibacterial therapy for impetigo. Beyond efficacy and safety, antimicrobial susceptibility and pharmacological characteristics of the agent are essential points. Formulation of the antimicrobial product is fundamental, as well as patient and caregiver preference, to facilitate therapeutic adherence, to achieve the infection control, and to obtain the best benefit from treatment ( 2023; 84:XXXXXX).

Citing Articles

Alginate and Chitosan-Based Hydrogel Enhance Antibacterial Agent Activity on Topical Application.

Wathoni N, Suhandi C, Ghassani Purnama M, Mutmainnah A, Nurbaniyah N, Syafra D Infect Drug Resist. 2024; 17:791-805.

PMID: 38444772 PMC: 10913799. DOI: 10.2147/IDR.S456403.

Formulation and Optimization of Solid Lipid Nanoparticle-based Gel for Dermal Delivery of Linezolid using Taguchi Design.

Chauhan I, Singh L Recent Adv Antiinfect Drug Discov. 2024; 19(4):322-347.

PMID: 38243985 DOI: 10.2174/0127724344280309240103062810.

References

Abrha S, Tesfaye W, Thomas J . Intolerable Burden of Impetigo in Endemic Settings: A Review of the Current State of Play and Future Directions for Alternative Treatments. Antibiotics (Basel). 2020; 9(12). PMC: 7765423. DOI: 10.3390/antibiotics9120909. View

Dhingra D, Parakh A, Ramachandran S . Retapamulin: a newer topical antibiotic. J Postgrad Med. 2013; 59(2):127-30. DOI: 10.4103/0022-3859.113842. View

Schachner L, Andriessen A, Benjamin L, Claro C, Eichenfield L, Esposito S . Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo. J Drugs Dermatol. 2021; 20(2):134-142. DOI: 10.36849/JDD.5745. View

Yilmaz E, Aslantas O . Antimicrobial resistance and underlying mechanisms in Staphylococcus aureus isolates. Asian Pac J Trop Med. 2017; 10(11):1059-1064. DOI: 10.1016/j.apjtm.2017.10.003. View

Davino G, DAlvano T, Esposito S . The Use of Ozenoxacin in Pediatric Patients: Clinical Evidence, Efficacy and Safety. Front Pharmacol. 2020; 11:559708. PMC: 7751750. DOI: 10.3389/fphar.2020.559708. View

Kardas P, Lewek P, Matyjaszczyk M . Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013; 4:91. PMC: 3722478. DOI: 10.3389/fphar.2013.00091. View

Eicher L, Knop M, Aszodi N, Senner S, French L, Wollenberg A . A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019; 33(12):2253-2263. DOI: 10.1111/jdv.15913. View

Iannini P, Mandell L, Felmingham J, Patou G, Tillotson G . Adverse cutaneous reactions and drugs: a focus on antimicrobials. J Chemother. 2006; 18(2):127-39. DOI: 10.1179/joc.2006.18.2.127. View

Veien N . The clinician's choice of antibiotics in the treatment of bacterial skin infection. Br J Dermatol. 1999; 139 Suppl 53:30-6. DOI: 10.1046/j.1365-2133.1998.1390s3030.x. View

10.

Vassileva S, Mateev G, Parish L . Antimicrobial photosensitive reactions. Arch Intern Med. 1998; 158(18):1993-2000. DOI: 10.1001/archinte.158.18.1993. View

11.

Galli L, Venturini E, Bassi A, Castelli Gattinara G, Chiappini E, Defilippi C . Common Community-acquired Bacterial Skin and Soft-tissue Infections in Children: an Intersociety Consensus on Impetigo, Abscess, and Cellulitis Treatment. Clin Ther. 2019; 41(3):532-551.e17. DOI: 10.1016/j.clinthera.2019.01.010. View

12.

Zhanel G, Adam H, Baxter M, Lagace-Wiens P, Karlowsky J . In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18). J Antimicrob Chemother. 2021; 76(7):1808-1814. DOI: 10.1093/jac/dkab098. View

13.

Conly J, Johnston B . Mupirocin - Are we in danger of losing it?. Can J Infect Dis. 2007; 13(3):157-9. PMC: 2094870. DOI: 10.1155/2002/692581. View

14.

Smith R, Russo J, Fiegel J, Brogden N . Antibiotic Delivery Strategies to Treat Skin Infections When Innate Antimicrobial Defense Fails. Antibiotics (Basel). 2020; 9(2). PMC: 7168299. DOI: 10.3390/antibiotics9020056. View

15.

Kosar L, Laubscher T . Management of impetigo and cellulitis: Simple considerations for promoting appropriate antibiotic use in skin infections. Can Fam Physician. 2017; 63(8):615-618. PMC: 5555330. View

16.

Thomson K, Thomson G, Biehle J, Deeb A, Crawford J, Herrera R . A Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Streptococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi. Curr Ther Res Clin Exp. 2016; 83:8-12. PMC: 5026688. DOI: 10.1016/j.curtheres.2016.07.001. View

17.

Sakr A, Bregeon F, Mege J, Rolain J, Blin O . Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent Infections. Front Microbiol. 2018; 9:2419. PMC: 6186810. DOI: 10.3389/fmicb.2018.02419. View

18.

Alseqely M, Newton-Foot M, Khalil A, El-Nakeeb M, Whitelaw A, Abouelfetouh A . Association between fluoroquinolone resistance and MRSA genotype in Alexandria, Egypt. Sci Rep. 2021; 11(1):4253. PMC: 7896087. DOI: 10.1038/s41598-021-83578-2. View

19.

van Bijnen E, Paget J, den Heijer C, Stobberingh E, Bruggeman C, Schellevis F . Evidence-based primary care treatment guidelines for skin infections in Europe: a comparative analysis. Eur J Gen Pract. 2014; 20(4):294-300. DOI: 10.3109/13814788.2013.872621. View

20.

Lee A, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A . Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018; 4:18033. DOI: 10.1038/nrdp.2018.33. View